05: The Future of Psychedelics in Healthcare

The World as You’ll Know It: The Great Rebuild

Contenuto fornito da Aventine Research Institute. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Aventine Research Institute o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

2y ago 28:26

MP3•Pagina principale dell'episodio

Judith Warner speaks with Dr. Matthew Johnson about the state of psychedelic research today and the likelihood that certain drugs — MDMA and psilocybin specifically — could soon be approved for the treatment of conditions like addiction and PTSD. Psychedelics have long been known for their abilities to alter perception, but renewed interest by major research institutions in psychedelics’ ability to treat a range of common disorders has brought some of them to the precipice of FDA approval.

DR. JOHNSON is a professor of Psychiatry and Behavioral Sciences at Johns Hopkins University and a leader in the study of psychedelics for the treatment of addiction.

A transcript of their conversation can be found at Aventine.org/podcast.

To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy

Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

36 episodi

#Aventine Research Institute #Tech #Kurt Andersen